Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Head and Neck Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Thyroid Gland Carcinoma (359
)
Squamous Cell Carcinoma of Head and Neck (291
)
Nasopharyngeal Carcinoma (59
)
Salivary Gland Cancer (57
)
Oral Cancer (53
)
Oropharyngeal Cancer (23
)
Maxillary Sinus Carcinoma (6
)
Tongue Carcinoma (5
)
Thyroid Gland Carcinoma (359
)
Squamous Cell Carcinoma of Head and Neck (291
)
Nasopharyngeal Carcinoma (59
)
Salivary Gland Cancer (57
)
Oral Cancer (53
)
Oropharyngeal Cancer (23
)
Maxillary Sinus Carcinoma (6
)
Tongue Carcinoma (5
)
›
Associations
(561)
News
Trials
Search handles
@ANViswanathanMD
@A_CT_SimMDJD
@AnnaLeeMDMPH
@AnujkumarTvm
@AshleySumrallMD
@BijoyTelivala
@BruixolaGema
@CJTsaiMDPhD
@CancerConnector
@CyclingDoctor
@DKirschMDPhD
@DavidSherMD
@DocMCotant
@DrChoueiri
@DrChowdharyMD
@DrEmmaHolliday
@DrEzraCohen
@DrHaddadRobert
@DrHaigentz
@DrJNaidoo
@DrNabilSaba
@DrSteveMartin
@DrUppaluri
@Dr_Ivanoncologo
@Esanzgarcia
@HeadNeckMD
@HenningWillers
@JamesBatesMD
@Jbauml
@KaramLab
@Latinamd
@LeXiuning
@MCWardMD
@OmidHamidMD
@OncoRod
@OncoThor
@Prasshmehta
@RenoHemonc
@RielyMD
@SJFrankMD
@SantiCabezas1
@ShaalanBeg
@SorenBentzen
@SprakerMDPhD
@StephenVLiu
@SuyogCancer
@VivekSubbiah
@anita_turk
@binayshah
@drkevinknopf
@duvvuri_md
@j_luh
@jamecancerdoc
@jasonlukemd
@jdschoenfeld1
@jpaArmand
@msaerens01
@mtmdphd
@petra_jankowska
@pipcosper
@rbryanbell
@romeerizwan
@rushabh1388
@ryanhuey
@seanmmcbride
@sejadiMD
@subatomicdoc
@sueyom
@tmprowell
@toddscarbrough
@weldeiry
Search handles
@ANViswanathanMD
@A_CT_SimMDJD
@AnnaLeeMDMPH
@AnujkumarTvm
@AshleySumrallMD
@BijoyTelivala
@BruixolaGema
@CJTsaiMDPhD
@CancerConnector
@CyclingDoctor
@DKirschMDPhD
@DavidSherMD
@DocMCotant
@DrChoueiri
@DrChowdharyMD
@DrEmmaHolliday
@DrEzraCohen
@DrHaddadRobert
@DrHaigentz
@DrJNaidoo
@DrNabilSaba
@DrSteveMartin
@DrUppaluri
@Dr_Ivanoncologo
@Esanzgarcia
@HeadNeckMD
@HenningWillers
@JamesBatesMD
@Jbauml
@KaramLab
@Latinamd
@LeXiuning
@MCWardMD
@OmidHamidMD
@OncoRod
@OncoThor
@Prasshmehta
@RenoHemonc
@RielyMD
@SJFrankMD
@SantiCabezas1
@ShaalanBeg
@SorenBentzen
@SprakerMDPhD
@StephenVLiu
@SuyogCancer
@VivekSubbiah
@anita_turk
@binayshah
@drkevinknopf
@duvvuri_md
@j_luh
@jamecancerdoc
@jasonlukemd
@jdschoenfeld1
@jpaArmand
@msaerens01
@mtmdphd
@petra_jankowska
@pipcosper
@rbryanbell
@romeerizwan
@rushabh1388
@ryanhuey
@seanmmcbride
@sejadiMD
@subatomicdoc
@sueyom
@tmprowell
@toddscarbrough
@weldeiry
Filter by
Latest
9ms
Session #2 with #HeadAndNeckCancer experts @DrNabilSaba, Mark El-Deiry, MD, FACS, and Bill Stokes, MD is taking place now at #DDHO2023. (@BioAscend)
9 months ago
9ms
Impressive phase II results for target vol deescalation in RT for #hncsm and great thread. Would love to see the AI model rolled out prospectively to multiple centers. Congrats @DavidSherMD and team! (@BoekeSimon)
9 months ago
Clinical • P2 data
9ms
Editorial: "Epstein–Barr Virus DNA Screening in Asymptomatic People without Known Nasopharyngeal Cancer," by @EIzumchenko and @eevokes. https://t.co/9hutbgzZel #cfDNA #NPC #Oncology @UChicagoHemOnc @UChicagoMed https://t.co/eKtN1fNmIp (@NEJMEvidence)
9 months ago
9ms
Kudos to @KimmelCancerCtr for recently enrolling a patient in #clinicaltrial EA3202! This trial aims to improve results for patients w/ advanced-stage #HeadAndNeckCancer by comparing several treatment approaches. More: https://t.co/w1CHkFS7tG #HNCA #HNCASM cc: @AartiBhatiaMD (@eaonc)
9 months ago
Clinical • Metastases
9ms
ASP-1929 + anti-PD-1 therapy in patients with locoregional/metastatic head and neck squamous cell carcinoma demonstrated an objective response rate of 29.4%. #HNSCC #hancsm | @MDAndersonNews @agillenw https://t.co/qUls97yI3r (@TargetedOnc)
9 months ago
Clinical • Metastases
|
Akalux (cetuximab sarotalocan)
9ms
☢️👃Upper-neck irradiation 🆚standard whole-neck irradiation in nasopharyngeal carcinoma Systematic #review and #meta-analysis by multiple centers researchers 🔗https://t.co/qYwyTQ9yJ5 #radonc #hncsm @StAr_MCM74 (@TumoriJ)
9 months ago
Retrospective data • Review
9ms
🎧In this podcast, we hear from @EzraACohen, @DrNabilSaba, @AriRosenbergMD, @BlessieNelson & @HSkinnerMDPhD as they share insights and updates in immunotherapy for head & neck cancer from #ASCO23: Listen here ➡️https://t.co/K7VjodkEHY⬅️ @ASCO #hncSM #ImmunoOnc (@VJOncology)
9 months ago
9ms
Thanks @NIDCR @NIH for this #K99/R00 Pathway to Independence Award! Extremely grateful and equally excited to work with a team of incredible mentors @GPratx @JohnSunwooMD @Qle_stanford and collaborators across @StanfordMed @StanfordEng ! #HNSCC #Cancer #Organoids #Bioprinting (@SYAMANTAkHAN)
9 months ago
9ms
@gdurm getting us to a lunch break with a great review of #ASCO23 head and neck cancer abstracts @IUCancerCenter (@anita_turk)
9 months ago
Review
9ms
Onwards and upwards (above the clavicles), @hfuentesbayne (my boss in the CUP Clinic at Mayo 😀) provides an outstanding review of advances in the management of patients with head and neck cancers. (@OncoThor)
9 months ago
Clinical • Review
9ms
Seminars in Radiation Oncology @ElsevierConnect is pleased to share "Lessons and Opportunities for Biomarker-Driven Radiation Personalization in Head and Neck Cancer" by Dr. Rahimy @Stanford, Dr. Gensheimer @MFGensheimer,...Dr. Quynh-Thu Le @Qle_stanford. https://t.co/PzVnPgFAvK (@ANViswanathanMD)
9 months ago
9ms
@CelSciCorp in continuing discussions w/ @FDAOncology regarding Multikine in SCCHN. $CVM preparing additional materials for next FDA meeting while concurrently pursuing EU, UK & Canada approval. CVM says🇨🇦approval could come as soon as '24. https://t.co/yrWqtbFvCf (@vanjohn10)
9 months ago
FDA event
|
Multikine (leukocyte interleukin injection)
9ms
This week on @CleClinicMD, Cancer advances, Shlomo Koyfman, MD, Director of Head and Neck and Skin Radiation, joins @ShepardDale to discuss SBRT therapy benefits and challenges for head and neck cancer treatment. https://t.co/TcldxnC2vr #CleClinicCancer (@italgal22)
9 months ago
9ms
Last weekend @headneckMD presented data from a Phase 1 study showing that allogeneic cytokine-induced memory-like NK cells plus ImmunityBio’s IL-15 superagonist N-803 can induce tumor regression in advanced head and neck #cancer patients. Read more: https://t.co/qnsv4FeB5D $IBRX (@ImmunityBio)
9 months ago
Clinical • Metastases
|
Anktiva (inbakicept)
9ms
Targeting both EGFR-positive tumors and PD-1 blockade may result in improved tumor shrinkage, says our Dr. Ann Gillenwater, suggesting further study to assess its potential as a new therapy for recurrent head and neck cancer. https://t.co/8AG8Cdbo05 @OncLive @agillenw #EndCancer (@MDAndersonNews)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR positive
9ms
We are seeing a lot of head and neck cancers at the hospital. Almost all are fully jabbed. (@PatriotSkyrific)
9 months ago
Clinical
9ms
Honored to moderate @AHNSinfo International Meeting in Montreal on consensus of surgical margins for head and neck cancer. Great panel of experts! @VinPaleri @EbenRosenthal #AHNS2023 #surgicaloncology #TORS (@TopfHNS)
9 months ago
9ms
Thanks for sharing your story @DickieV and helping to raise awareness on #throatcancer #vocalcord as a @NovaMBB fan and head and neck surgical oncologist wishing you a speedy recovery @HNSurgeon @DrUppaluri @ScarlessThyroid (@TopfHNS)
9 months ago
9ms
This study developed an oral cancer survival calculator with 22,392 oral cancer pts from SEER. These pts have a higher risk of death from other (non-cancer) causes than their matched US population, and this risk increases by stage @JAMAOto @LouiseDaviesMD https://t.co/iXvXT8fs4F (@PiccirilloJay)
9 months ago
Clinical
9ms
Our mem-like NK cell trial led by @HeadNeckMD showing promising results in combination with N-803 in advanced Head & Neck cancer. @DanaFarber @DanaFarberNews https://t.co/g3cpIrDJA1 (@romeerizwan)
9 months ago
Combination therapy • Metastases
|
Anktiva (inbakicept)
9ms
Dr. @MNagasaka plays a key role in the multidisciplinary treatment of thoracic and head-and-neck malignancies at the Barbara Ann Karmanos Cancer Institute, specializing in molecular targeting and novel immunotherapy. She has more than a decade of experience in treating lung… https://t.co/eSVSE8EV9L (@cancerGRACE)
9 months ago
9ms
A wonderful and timely discussion for sure - was great to join such a talented group. @DrUppaluri, Doug Adkins, and many others have been really advancing the neoadjuvant paradigm in #headandneck #cancer. Feels like a matter of time before this is standard of care. (@SidPuram)
9 months ago
Clinical
9ms
We found something quite similar in intermediate- and high-risk oropharynx cancer. Whether or not the imaging appearance accurately predicts pathologic ENE status (very iffy), there is a signal that radiologic matting is a legitimate marker for prognosis. https://t.co/l1w6YkfVn9 (@DavidSherMD)
9 months ago
9ms
Dr. Tsung-Lin Yang and Dr. Allen Ho at the 2023 AHNS International Conference on Head and Neck Cancer! @allenhomd @AHNSinfo #thyroidcancer #AHNS2023 (@AHNSEndo)
9 months ago
9ms
Any docs/institutions out there with written guidelines/criteria on when to trigger a replan based on H&N CBCT? Threshold seems subjective - hard to standardize. #hncsm #radonc @DavidSherMD @CJTsaiMDPhD @seanmmcbride @DrNikhilJoshiMD @ShaunaRadOnc @JahanMohiuddin (@MCWardMD)
9 months ago
9ms
Highlights of the Milton Dance Symposium this morning included a thought-provoking discussion of the downfalls of use of MTD in trials, and a mandate for better incorporation of patient QOL endpoints into trials in #hncsm @Qle_stanford (@henson_md)
9 months ago
Clinical
9ms
Oral Cancer Patients Face Worse Outcomes With Delayed Radiation Therapy https://t.co/MIOAcBrIDq @sueyom (@UCSFCancer)
9 months ago
Clinical
9ms
🔥frm IJSO press: CT Screening for Pulmonary Mets in HNSCC Large cohort study, utility of CT, cost saving over PETCT https://t.co/I3C2SJaGrB @drshreyashukla @ujjwalagarwalmd @drvaishricha @docdcruz @pankajch37 @VanitaNoronha @sarbani30 @DrArpitaSahu @DrVijayPatil11 @Kajari16 (@AMCancerImaging)
9 months ago
HEOR
9ms
@MoffittNews at the @AHNSinfo #AHNS23! @JJCaudell #headandneckcancer #medtwitter (@mcmullen_dr)
9 months ago
9ms
Can anyone tell biopsy is needed for oral cancer and should i go ahead with biopsy test from dentist , my mom is suffering from oral dieseas dentist advise us a biopsy, and told us i can do a test, anyone who can advise us plz 🙏 @Trolling_isart @BreastSurgeonGA (@techguruimran)
9 months ago
Biopsy
9ms
It’s difficult to conclude that there is no clinical benefit when various histologies have been included (56% being head and neck tumors and urothelial tumors) 👉🏼we need studies with same histologies!!!!! (@OncoRod)
9 months ago
Clinical
9ms
Kicking off day 2 #AHNS23 with @GeneCollector discussing Opportunities and Challenges in the area of Precision Medicine. Understanding the complexity and heterogeneity of head and neck cancer is key to moving forward. New Javelin data coming soon. @CleClinicMD @nataliesilvermd (@ShaunaRadOnc)
9 months ago
9ms
Congratulations to Dr. Tim Chan @GeneCollector, the 2023 @AHNSinfo John Conely lecturer, who gave a brilliant keynote reviewing his transformational work on tumor mutational burden and immunotherapy for HNSCC and other tumors. Bravo! (@rbryanbell)
9 months ago
Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
9ms
@GeneCollector making HNSCC immunology simple and promising #AHNS2023 @AHNSinfo @RambamHCC (@SaeedSalmanMD)
9 months ago
9ms
Excellent presentation by @AvaCongFan at #AHNS23 discussing the association of radiographic ENE with risk of DM in HPV associated oropharynx cancer. @CleClinicHNI @ShlomoKoyfmanMD @YilmazMDPhD (@ShaunaRadOnc)
9 months ago
9ms
In our session on unusual research techniques today at #AHNS2023 , we discussed the Delphi consensus method, the importance of harmonization of trial endpoints, and the utility of AI in head and neck cancer. @sueyom @henson_md @SujithBaliga Thanks to all who joined us! (@H_N_C_I_G)
9 months ago
9ms
This study not relevant anymore in second-line because shifting IO to first-line#first-line study efti+pembro coming to an end👊👊#chemo-free regimens welcome in HNSCC💥 (@WLybaert)
9 months ago
Clinical
|
Keytruda (pembrolizumab)
9ms
Packed house for the @AHNSinfo #TORS section. WOW! @HNSurgeon @ScarlessThyroid @DrOrosco @EbenRosenthal excited to learn about the most up to date evidence for transoral robotic surgery and #oropharynxcancer (@TopfHNS)
9 months ago
Surgery
9ms
Next Generation Radiotherapy: Andrew B. Sharabi, @YvonneMowery, Xiao-Jing Wang, #aacrAHNS23 cochair Sana D. @KaramLab, @ColetteShenMD, and @KimpleRandall addressed this topic in a plenary session on Friday at the AACR-AHNS Head and Neck Cancer Conference. (@AACR)
9 months ago
9ms
@SJFrankMD dileaneated about Oropharyngeal cancers. He highlighted it's increasing prevalence, diagnosis, treatment & clinical outcomes. He shared his expertise to resolve doubts & hurdles faced while treating such cancers. #3rdApolloAnnualProtonPracticum #WinningOverCancer (@ApolloProton)
9 months ago
Clinical • Clinical data
9ms
.@sueyom, @DrHaddadRobert, Nicole C. Schmitt, Angela L. Ferguson, and Barbara A. Burtness discussed "Clinical Trials" in a plenary session today at the AACR-AHNS Head and Neck Cancer Conference. #aacrAHNS23 (@AACR)
9 months ago
Clinical
10ms
En route! Looking forward connecting with colleagues & to presenting our work on neoadjuvant immunoradiotherapy for head and neck cancer @AHNSinfo 2023. @providence @ChilesResearch @romleidner @CalifanoMd @KaramLab @MaieStJohn @rsaddawi @DrEzraCohen #AHNS2023 (@rbryanbell)
10 months ago
Clinical
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login